Warren Marks
Neurology with Special Qualifications in Child Neurology · Fort Worth, TXNPI 1285727370
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $41,025 of the $58,201 with a category attached, or 70.5%. 16 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 37.6% of the total. Reporting peaked in 2022 at $17,758 and has fallen 98.8% since, to $211 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 80 payments — averaging $727.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$22K
- PTC Therapeutics, Inc.$19K
- Catalyst Pharmaceuticals, Inc.$5K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$5K
- Genentech USA, Inc.$4K
- Neurocrine Biosciences, Inc.$1K
- plus $2K from 10 others
Across 68 payments — averaging $2287.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$37K
- PTC Therapeutics, Inc.$34K
- Sarepta Therapeutics, Inc.$33K
- NS Pharma, Inc.$27K
- Novartis$25K
What the payments were for
- Consulting fees$41,02570%
- Speaking & faculty fees$8,43014%
- Travel & lodging$4,6518%
- Food & beverage$4,0967%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 20 | $21,878 |
| PTC Therapeutics, Inc. | 14 | $19,411 |
| Catalyst Pharmaceuticals, Inc. | 9 | $4,866 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $4,530 |
| Genentech USA, Inc. | 4 | $3,974 |
| Neurocrine Biosciences, Inc. | 12 | $1,480 |
| Genentech, Inc. | 4 | $905 |
| Ipsen Biopharmaceuticals, Inc | 3 | $295 |
| UCB, Inc. | 2 | $225 |
| Biogen | 4 | $152 |
| Greenwich Biosciences, Inc. | 1 | $126 |
| Medtronic | 1 | $125 |
| Biomarin Pharmaceutical Inc. | 1 | $119 |
| Orthopediatrics Corp. | 1 | $76 |
| Novartis | 1 | $24 |
| ITF Therapeutics LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$58,201 in reported general payments places this provider in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxcarbazepine | 14 | $1,861 |
| Levetiracetam | 20 | $252 |
| Zonisamide | 11 | $205 |
| Baclofen | 13 | $125 |
| Clonidine Hcl | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Fort Worth
- Michael PerryFort Worth$162K
- Stephanie AcordFort Worth$12K
- Dave ShahaniFort Worth$8K
- Cynthia KeatorFort Worth$5K
- Brittney RhemFort Worth$5K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.